Cargando…

Psychiatric and behavioral adverse events in randomized clinical studies of the noncompetitive AMPA receptor antagonist perampanel

OBJECTIVE: Perampanel, a selective, noncompetitive α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazolepropionic acid (AMPA) glutamate receptor antagonist, is indicated for adjunctive treatment of partial seizures in patients ≥12 years based on three phase III clinical studies. The perampanel U.S. Prescribing Inf...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ettinger, Alan B., LoPresti, Antonia, Yang, Haichen, Williams, Betsy, Zhou, Sharon, Fain, Randi, Laurenza, Antonio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2015
Materias:	Full‐length Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4758397/ https://www.ncbi.nlm.nih.gov/pubmed/26140524 http://dx.doi.org/10.1111/epi.13054

Ejemplares similares

Cognitive effects of adjunctive perampanel for partial‐onset seizures: A randomized trial
por: Meador, Kimford J., et al.
Publicado: (2016)

Noncompetitive antagonists induce cooperative AMPA receptor channel gating
por: Shi, Edward Y., et al.
Publicado: (2019)

Perampanel efficacy and tolerability with enzyme-inducing AEDs in patients with epilepsy
por: Gidal, Barry E., et al.
Publicado: (2015)

Assessment of the long‐term efficacy and safety of adjunctive perampanel in tonic‐clonic seizures: Analysis of four open‐label extension studies
por: Rektor, Ivan, et al.
Publicado: (2020)

Perampanel efficacy and safety by gender: Subanalysis of phase III randomized clinical studies in subjects with partial seizures
por: Vazquez, Blanca, et al.
Publicado: (2015)

Perampanel and pregnancy
por: Vazquez, Blanca, et al.
Publicado: (2021)

Open‐label study to investigate the safety and efficacy of adjunctive perampanel in pediatric patients (4 to <12 years) with inadequately controlled focal seizures or generalized tonic‐clonic seizures
por: Fogarasi, Andras, et al.
Publicado: (2020)

AMPA receptor antagonist perampanel affects glioblastoma cell growth and glutamate release in vitro
por: Lange, Falko, et al.
Publicado: (2019)

The AMPA receptor antagonist perampanel suppresses epileptic activity in human focal cortical dysplasia
por: Brito da Silva, Anderson, et al.
Publicado: (2022)

Therapeutic potential of AMPA receptor antagonist perampanel against cerebral ischemia: beyond epileptic disorder
por: Suda, Satoshi, et al.
Publicado: (2019)

Real‐world analysis of hospitalizations in patients with epilepsy and treated with perampanel
por: Faught, Edward, et al.
Publicado: (2021)

Efficacy and safety of adjunctive perampanel 4 mg/d for the treatment of focal seizures: A pooled post hoc analysis of four randomized, double‐blind, phase III studies
por: Steinhoff, Bernhard J., et al.
Publicado: (2020)

Perampanel Inhibition of AMPA Receptor Currents in Cultured Hippocampal Neurons
por: Chen, Chao-Yin, et al.
Publicado: (2014)

Effect of perampanel, a novel AMPA antagonist, on benzodiazepine-resistant status epilepticus in a lithium-pilocarpine rat model
por: Hanada, Takahisa, et al.
Publicado: (2014)

The AMPA receptor antagonist perampanel robustly rescues amyotrophic lateral sclerosis (ALS) pathology in sporadic ALS model mice
por: Akamatsu, Megumi, et al.
Publicado: (2016)

The Novel Direct Modulatory Effects of Perampanel, an Antagonist of AMPA Receptors, on Voltage-Gated Sodium and M-type Potassium Currents
por: Lai, Ming-Chi, et al.
Publicado: (2019)

Perampanel, a potent AMPA receptor antagonist, protects against tetramethylenedisulfotetramine-induced seizures and lethality in mice: comparison with diazepam
por: Zolkowska, Dorota, et al.
Publicado: (2021)

Perampanel in real‐world clinical care of patients with epilepsy: Interim analysis of a phase IV study
por: Wheless, James, et al.
Publicado: (2020)

Assessment of Cannabinoids Agonist and Antagonist in Invasion Potential of K562 Cancer Cells
por: Gholizadeh, Fatemeh, et al.
Publicado: (2019)

HLAs associated with perampanel-induced psychiatric adverse effects in a Korean population
por: Jang, Yoonhyuk, et al.
Publicado: (2020)

Long-term safety of perampanel and seizure outcomes in refractory partial-onset seizures and secondarily generalized seizures: Results from phase III extension study 307
por: Krauss, Gregory L, et al.
Publicado: (2014)

The broad-spectrum activity of perampanel: state of the art and future perspective of AMPA antagonism beyond epilepsy
por: Perversi, Fabio, et al.
Publicado: (2023)

Examining the daily relationship between guilt, shame, and substance use among veterans with psychiatric disorders
por: Aurora, Pallavi, et al.
Publicado: (2023)

Evaluation of perampanel as monotherapy for focal seizures: Experience from open-label extension studies
por: Kwan, Patrick, et al.
Publicado: (2017)

Exposure to adversity and inflammatory outcomes in mid and late childhood
por: O'Connor, Meredith, et al.
Publicado: (2020)

Efficacy and safety of perampanel monotherapy in patients with focal‐onset seizures with newly diagnosed epilepsy or recurrence of epilepsy after a period of remission: The open‐label Study 342 (FREEDOM Study)
por: Yamamoto, Takamichi, et al.
Publicado: (2020)

Impact of perampanel on pharmacokinetics of concomitant antiepileptics in patients with partial‐onset seizures: pooled analysis of clinical trials
por: Majid, Oneeb, et al.
Publicado: (2016)

Synthesis and Pharmacological Evaluation of Triazolopyrimidinone Derivatives as Noncompetitive, Intracellular Antagonists for CC Chemokine Receptors 2 and 5
por: Ortiz Zacarías, Natalia V., et al.
Publicado: (2019)

Design, synthesis and activity evaluation of mannose-based DC-SIGN antagonists
por: Obermajer, Nataša, et al.
Publicado: (2010)

Efficacy and safety of adjunctive perampanel in patients with focal seizures or generalized tonic‐clonic seizures: Post hoc analysis of Phase II and Phase III double‐blind and open‐label extension studies in India
por: Mehndiratta, Man M., et al.
Publicado: (2021)

The effect of adverse and positive experiences on inflammatory markers in Australian and UK children
por: Priest, Naomi, et al.
Publicado: (2022)

Demographic and psychiatric correlates of compulsive sexual behaviors in gambling disorder
por: Cowie, Megan E., et al.
Publicado: (2019)

Subjective sleep quality and sleep duration of patients in a psychiatric hospital
por: Müller, Matthias J., et al.
Publicado: (2016)

Inflammation subtypes in psychosis and their relationships with genetic risk for psychiatric and cardiometabolic disorders
por: Zhang, Lusi, et al.
Publicado: (2022)

Decreased epileptogenesis in mice lacking the System x(c) (−) transporter occurs in association with a reduction in AMPA receptor subunit GluA1
por: Sears, Sheila M. S., et al.
Publicado: (2019)

Sustained vascular contractile response induced by an R- and S-epimer of the ergot alkaloid ergocristine and attenuation by a noncompetitive antagonist
por: Cherewyk, Jensen E, et al.
Publicado: (2022)

Knowledge and attitudes of medical staff in Chinese psychiatric hospitals regarding COVID-19
por: Shi, Yudong, et al.
Publicado: (2020)

Correlates of C-reactive protein with neural reward circuitry in adolescents with psychiatric symptoms
por: Liu, Qi, et al.
Publicado: (2020)

Efficacy and adverse reactions of perampanel in the treatment of epilepsy in children
por: Li, Dan, et al.
Publicado: (2022)

The effect of COVID-19 vaccination on anticoagulation stability in adolescents and young adults using vitamin K antagonists()
por: Visser, Chantal, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_agimcj04rj83tregrvtj9434rr